- Home
- FHB vs AKRO Comparison
FHB vs AKRO Comparison
Compare FHB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHB
- AKRO
- Stock Information
- Founded
- FHB 1858
- AKRO 2017
- Country
- FHB United States
- AKRO United States
- Employees
- FHB N/A
- AKRO N/A
- Industry
- FHB Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FHB Finance
- AKRO Health Care
- Exchange
- FHB Nasdaq
- AKRO Nasdaq
- Market Cap
- FHB 3.3B
- AKRO 3.9B
- IPO Year
- FHB 2016
- AKRO 2019
- Fundamental
- Price
- FHB $25.07
- AKRO $50.09
- Analyst Decision
- FHB Sell
- AKRO Strong Buy
- Analyst Count
- FHB 8
- AKRO 7
- Target Price
- FHB $26.81
- AKRO $81.57
- AVG Volume (30 Days)
- FHB 977.1K
- AKRO 997.3K
- Earning Date
- FHB 07-25-2025
- AKRO 08-08-2025
- Dividend Yield
- FHB 4.15%
- AKRO N/A
- EPS Growth
- FHB 11.02
- AKRO N/A
- EPS
- FHB 1.93
- AKRO N/A
- Revenue
- FHB $805,018,000.00
- AKRO N/A
- Revenue This Year
- FHB $10.34
- AKRO N/A
- Revenue Next Year
- FHB $2.65
- AKRO N/A
- P/E Ratio
- FHB $13.00
- AKRO N/A
- Revenue Growth
- FHB 0.27
- AKRO N/A
- 52 Week Low
- FHB $20.32
- AKRO $21.34
- 52 Week High
- FHB $28.80
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FHB 56.11
- AKRO 49.73
- Support Level
- FHB $23.57
- AKRO $47.10
- Resistance Level
- FHB $24.11
- AKRO $53.02
- Average True Range (ATR)
- FHB 0.46
- AKRO 2.14
- MACD
- FHB 0.06
- AKRO -0.01
- Stochastic Oscillator
- FHB 75.00
- AKRO 51.97
About FHB First Hawaiian Inc.
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.